tradingkey.logo

U.S. FDA Approves Combination Treatment Of Venclexta And Acalabrutinib For Previously Untreated Patients With Chronic Lymphocytic Leukemia

ReutersFeb 20, 2026 7:26 AM

- Abbvie Inc ABBV.N:

  • U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES COMBINATION TREATMENT OF VENCLEXTA® (VENETOCLAX) AND ACALABRUTINIB FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI